Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Onconova Therapeutics, Inc. Common Stock (ONTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. By using this site you agree to the "Onconova Therapeutics' stock is owned by a number of retail and institutional investors. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. -11,357.71% -115.25% Factset: FactSet Research Systems Inc.2019. Get today's Onconova Therapeutics Inc stock price and latest ONTX news as well as Onconova Therapeutics real-time stock quotes, technical analysis, full financials and more.
Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. Have Watchlists? Rio Tinto CEO resigns over destruction of caves In general, a lower number or multiple is usually considered better that a higher one. Copyright 2020 FactSet Research Systems Inc. All rights reserved. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Onconova Therapeutics employs 25 workers across the globe.Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. Get the latest Onconova Therapeutics Inc ONTX detailed stock quotes, stock …
Mark Image. Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, Steven M Fruchtman and Tyndall Capital Partners L P. ONTX stock was purchased by a variety of institutional investors in the last quarter, including Captrust Financial Advisors, FNY Investment Advisers LLC, and Jane Street Group LLC. Death toll rises to 10 in massive Northern California wildfire
Corporate bond issuance off to a bang in September The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.Onconova Therapeutics' management team includes the following people: So, when comparing one stock to another in a different industry, it's best make relative comparisons to that stock's respective industry values. ONTX: currency: USD Stock Common: ONCONOVA THERAPEUTICS INC: NASDAQ: ONTX: currency: USD : ONCONOVA THERAPEUTICS INC: ONTX: Latest USPTO Trademark Filings . ISTYBON. View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. Onconova Therapeutics, Inc. Common Stock (ONTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. As of July 31st, there was short interest totaling 11,490,000 shares, an increase of 46.4% from the July 15th total of 7,850,000 shares. The Onconova Therapeutics, Inc. stock forecast is 9.800 USD for 2021 September 08, Wednesday; and 67.040 USD for 2025 September 08, Monday with technical analysis. ONTX stock was acquired by a variety of institutional investors in the last quarter, including Captrust Financial Advisors, FNY Investment Advisers LLC, and Jane Street Group LLC. Announces Closing of $11.0 Million Public Offering. Benzinga +19.82%. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. This suggests a possible upside of 519.3% from the stock's current price.
One share of ONTX stock can currently be purchased for approximately $0.24.Onconova Therapeutics has a market capitalization of $44.00 million and generates $2.18 million in revenue each year. Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Azarenka stuns Serena Williams in U.S. Open semifinal Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. Let’s briefly compare Onconova (ONTX) stock to its peers. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. All times are ET. Get the latest Onconova Therapeutics Inc ONTX detailed stock quotes, stock … With a price/sales ratio of 192.17, Onconova Therapeutics Inc has a higher such ratio than 98.07% of stocks in our set.